Atlanta—The factor Xa inhibitor edoxaban (Savaysa, Daiichi-Sankyo) reduced occurrences of cancer-associated venous thromboembolism (VTE) as well as low-molecular-weight heparin (LMWH)—the current standard of care—according to the multicenter Hokusai VTE Cancer study presented at the 2017 annual meeting of the American Society of Hematology.
The findings are significant because although current guidelines recommend the use of LMWH therapy for cancer-associated VTE,